• C A Kenaan, R L Estacio, and G B Bikhazi.
• Department of Anesthesiology, University of Miami/Jackson Memorial Medical Center, Miami, FL 33101, USA.
• J Clin Anesth. 2000 May 1;12(3):173-6.

Study ObjectivesTo determine the pharmacodynamics and intubating conditions of cisatracurium 0.2 mg/kg in children aged 2 to 12 years.DesignOpen-label, randomized study.SettingOperating room of a university-affiliated hospital.Patients42 ASA physical status I and II patients, 24 to 155 months of age.InterventionsPatients were assigned to one of two groups: halothane anesthesia (G1) and opioid anesthesia (G2). Subsequently, each group was divided into two age subgroups: 24-59 months and 60-155 months. All patients were premedicated with midazolam intranasal 0.1 to 0.2 mg/kg. In G1, anesthesia was induced with halothane up to 3% and N(2)O/O(2) (60-70/30-40%). Halothane was reduced to Measurements And Main ResultsOnly first twitch (T(1)) recovery to 25% was significantly longer in patients aged 24 to 59 months who received halothane-based anesthesia, compared with those who received opioid-based anesthesia (p < 0.05). Onset time, maximum block, and intubating conditions did not differ between groups (p > 0.05).ConclusionsCisatracurium 0.2 mg/kg offered acceptable intubating conditions at 90 seconds in 98% of pediatric patients, regardless of the anesthesia-based technique. Longer clinical duration in the halothane group in younger children may be due to age-related potentiation or to the small number of patients enrolled in the younger subgroup.

16 keywords...

hide…